Baird Financial Group, Inc. Intra Cellular Therapies, Inc. Transaction History
Baird Financial Group, Inc.
- $50.4 Billion
- Q4 2024
A detailed history of Baird Financial Group, Inc. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 64,474 shares of ITCI stock, worth $8.49 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
64,474
Previous 47,763
34.99%
Holding current value
$8.49 Million
Previous $3.49 Million
54.18%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding ITCI
# of Institutions
418Shares Held
87.7MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.28 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$833 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$675 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$428 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$423 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...